-
OnKure Therapeutics Inc. (OKUR) PT Lowered to $27 at H.C. Wainwright
-
OnKure Therapeutics (OKUR) Misses Q3 EPS by 109c
-
OnKure Therapeutics (OKUR) Misses Q2 EPS by 114c
-
OnKure Therapeutics (OKUR) Tops Q1 EPS by 119c
-
Evercore ISI Starts OnKure Therapeutics Inc. (OKUR) at Outperform
-
OnKure Therapeutics Inc. (OKUR) PT Lowered to $34 at H.C. Wainwright
-
OnKure Therapeutics, Inc. (OKUR) Misses Q4 EPS by 130c
-
Jones Trading Starts OnKure Therapeutics Inc. (OKUR) at Buy, PT $32
-
OnKure (OKUR) Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219
-
Leerink Partners Starts OnKure Therapeutics Inc. (OKUR) at Outperform
-
Oppenheimer Starts OnKure Therapeutics Inc. (OKUR) at Outperform
-
OnKure Therapeutics (OKUR) Completes Merger with Reneo Pharmaceuticals, Concurrent $65M Private Placement

